Skip to main content
FDA grants RMAT status to Mustang's bubble boy disease gene therapy
8/23/2019

Mustang Bio's lentiviral gene therapy MB-107 gained the FDA's Regenerative Medicine Advanced Therapy designation as a treatment for X-linked severe combined immunodeficiency, commonly known as bubble boy disease. Mustang Bio and St. Jude Children's Research Hospital are co-developing the therapy.

Full Story: